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Summary. The present paper completes our recent study
on the effects of phytoestrogen ferutinin in preventing
osteoporosis and demonstrating the superior
osteoprotective effect of a 2 mg/kg/day dose in
ovariectomized (OVX) rats, compared to both estrogens
and lower (0.5, 1 mg/kg/day) ferutinin doses.
Morphological and morphometrical analyses were
performed on the effects of different doses of ferutinin
administrated for one month on uterus and on mammary
gland of Sprague-Dawley OVX rats, evaluated in
comparison with the results for estradiol benzoate. To
verify whether ferutinin provides protection against
uterine and breast cancer, estimations were made of both
the amount of cell proliferation (by Ki-67), and the
occurrence of apoptosis (by TUNEL), two processes that
in unbalanced ratio form the basis for cancer onset. The
results suggest that the effects of ferutinin are dose
dependent and that a 2 mg/kg/day dose might offer a
better protective action against the onset of both breast
and uterine carcinoma compared to ferutinin in lower
doses or estradiol benzoate, increasing cellular apoptosis
in glandular epithelia. 
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Introduction
Phytoestrogen ferutinin acts as an estrogen agonist
by binding to the estrogen receptors and generating
estrogen-induced responses (Appendino et al., 2002;
Ikeda et al., 2002). Previous studies by the authors have
shown that ferutinin exerts an osteoprotective action in
ovariectomized rats, preventing bone loss or enhancing
the recovery of lost bone mass resulting from severe
estrogen deficiency (Palumbo et al., 2009; Ferretti et al.,
2010). The authors recently demonstrated that the effect
of ferutinin on bone appears to be dose dependent, and a
2 mg/kg/day dose appears to be more effective in
preserving bone mass compared to both estrogens and
lower ferutinin doses (0.5 and 1 mg/kg/day), particularly
in skeletal regions with higher metabolic activity,
presumably because it inhibits osteoclast activity
(Cavani et al., 2012) rather than increasing bone
deposition as previously proposed (Palumbo et al.,
2009). Numerous data reported in the literature
regarding phytoestrogens, together with the authors’
studies to date agree in suggesting that ferutinin could be
employed as an anti-osteoporosis drug, and, at specific
doses, represent a good alternative to estrogen for use in
Hormone Replacement Therapy (HRT) during the peri-
menopausal period. 
It is well known that the positive osteoprotective
function of HRT is associated with a negative increased
risk of cancer in estrogen-sensitive organs, like the
uterus and mammary gland. Notwithstanding the huge
amount of data regarding the effects of phytoestrogens,
their beneficial and detrimental biological role in
estrogen-dependent malignancies are not well known.
Ferutinin dose-dependent effects on uterus 
and mammary gland in ovariectomized rats
Marzia Ferretti1, Francesco Cavani1, Paola Manni2, Gianluca 
Carnevale3, Laura Bertoni3, Manuela Zavatti3 and Carla Palumbo1
1Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze, Sezione di Morfologia umana, 2Dipartimento di Scienze della Vita
and 3Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con interesse Trapiantologico, Oncologico e di
Medicina Rigenerativa, Università di Modena e Reggio Emilia, Modena, Italy
Histol Histopathol (2014) 29: 1027-1037
Offprint requests to: Prof. Carla Palumbo, Università di Modena e Regio
Emilia, Dipartimento di Scienze Biomediche, Metaboliche e
Neuroscienze, Sezione di Morfologia Umana, c/o Istituti Anatomici -
Area Policlinico, Via del Pozo 71, 41125, Modena, Italy. e-mail:
carla.palumbo@unimore.it
http://www.hh.um.es
Histology and
Histopathology
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Despite the research reported in the literature, the role of
phytoestrogens in cancer remains controversial: there is
evidence for both inhibitory and stimulatory action on
cancer cell growth. It is important to underline that the
relationship between phytoestrogens and cancer
probably depends on various factors, like timing, mode
and dose of phytoestrogen administration, extraction
procedures from the plant of origin, and individual
metabolic differences of the targeted subjects. As
regards the beneficial effects, studies were performed in
which phytoestrogens appeared to be positive for
reducing the risk of estrogen-dependent cancers, for
example pre-menopausal (Lee et al., 1991; Hirose et al.,
1995; Wu et al., 1996; Yang et al., 2012) and post-
menopausal (Yuan et al., 1995) breast cancer. Regarding
isoflavones (phytoestrogens present in high
concentrations in legumes), these have been shown to be
effective as anti-cancer preventive agents, particularly in
breast, prostate, colon and gastric mucosa. An inverse
correlation seems to exist between the amount of
isoflavone-containing food ingested and the risk of
cancer (Shimizu et al., 1991; Barnes et al., 1995;
Kennedy, 1995; Wu et al., 2002; Yamamoto et al., 2003).
As regards the detrimental effects, i.e. the absence of
protection by reducing cancer risk and tumour
development, some evidence was found that certain
phytoestrogens can increase the risk of recurrence or
growth of existing tumours, through their estrogenic
properties (Messina et al., 2006; Duffy et al., 2007;
Mosquette et al, 2007; Gaete et al., 2012). Some authors
have shown that genistein (the most widely studied
phytoestrogen present in soy) can stimulate cancer in
colon (Rao et al., 1997) and mammary gland (Allred et
al., 2004a,b; Wang et al., 2006; El Sheikh Saad et al.,
2011) in rats fed with genistein-rich foods. Moreover,
genistein has been shown to increase the rate of tumour
growth in a dose-dependent manner in mice: the more
abundant the genistein diet content, the higher the rate of
tumour growth (Ju et al., 2001). However, genistein also
exhibits an anti-tumour action in mice, including
suppression of angiogenesis and induction of apoptosis,
if combined with polysaccharides (Yuan et al., 2003). In
in vitro studies, the proliferation of numerous types of
cancer cells were found to be markedly enhanced (Lucki
and Sewer, 2011) or inhibited (Yanagihara et al., 1993;
Messina et al., 1994) by phytoestrogens. Some of these,
like genistein and daidzein, exhibit a dose-dependent
effect: at low concentration they act exclusively as
estrogen agonists, while at higher concentrations they
have inhibitory effects on cellular growth (Martin et al.,
1978; Hsieh et al., 1998; de Lemos, 2001; Messina and
Loprinzi, 2001). These actions were found to contradict
the in vivo observations. 
The aim of the present study was to evaluate, for the
first time, the effects of different doses of ferutinin not
only on the uterus (the only existing literature data on
this topic were recently published by the authors
(Ferretti et al., 2012)), but also on the mammary gland of
ovariectomized rats. It is very important to establish
whether the same doses that provide the most beneficial
effects on bone against osteoporosis (Cavani et al., 2012)
also offer the best protection against excessive uterine
and breast cell proliferation. Enhanced proliferation is
undoubtedly a key process in the progression of
tumours, together with decreased programmed cell
death, i.e. apoptosis. Therefore, the present paper
evaluates both cell proliferation and apoptosis in the
epithelia of uterus endometrium and mammary gland of
ovariectomized rats treated with different doses of
ferutinin. 
Materials and methods
Animals and drugs
It should be noted that the data on uterus and
mammary glands reported in the present work were
collected on the same animal groups used in a previous
paper by the authors (Cavani et al., 2012). 
Thirty female Sprague-Dawley rats weighing 170-
200 g were purchased from Charles River (Calco, Lecco,
Italy). They were 7 weeks old according to the general
age-models used by Kalu (1991) and Fanti et al. (1998).
The rats were housed two per cage and maintained under
controlled conditions (22±1°C, 55-60% humidity, 12-h
light ⁄ 12-h dark). 
All experiments were carried out according to the
guidelines of the Bioethical Committee of the Italian
National Institute of Health. Animal care, maintenance
and surgery were conducted in accordance with Italian
law (D.L. no. 116 ⁄ 1992) and European legislation (EEC
no. 86 ⁄ 609).
Commercial rat pellets free of estrogenic substances
(Global Diet 2018; Mucedola s.r.l., Milan, Italy) and
drinking water were available ad libitum throughout the
whole experimental period. After 7 days of acclimation
to housing conditions, the rats were randomized into six
groups of 5 animals each: one group of rats was sham-
operated, whereas the rats of the other five groups were
ovariectomized. The rats were anesthetized in advance
by intraperitoneal administration with ketamine
hydrochloride (Ketavet 100®; Farmaceutici Gellini
S.p.a., Aprilia, Italy) plus xylazine hydrochloride
(Rompun®; Bayer, Leverkusen, Germany). To enter the
peritoneal cavity, surgery was performed by 1 centimeter
incision through the muscle layer. After extracting the
ovarian ducts, within a mass of adipose tissue, the
ovaries were identified and bilaterally removed. The rats
showed a time of revival and awakening from the
administration of anaesthesia of 30 minutes. The six
animal groups were indicated as follows:
SHAM: Sham-operated controls receiving vehicle
(5% Tween 80 in water)
C-OVX: Ovariectomized controls receiving vehicle
(5% Tween 80 in water)
EB-OVX: Ovariectomized treated with estradiol
benzoate 1.5 µg per rat twice a week
0.5F-OVX: Ovariectomized treated with ferutinin
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0.5 mg/kg/day
1F-OVX: Ovariectomized treated with ferutinin 1
mg/kg/day
2F-OVX: Ovariectomized treated with ferutinin 2
mg/kg/day
The operation of the SHAM group was performed in
the same way as the C-OVX group, but only exposing
the ovaries. Ferutinin was supplied by Indena S.p.a.
(Milan, Italy), solubilized in Tween 80 (5%) and
deionized water and administered in a volume of 5 ml/kg
by oral gavage. The dose of 2 mg/kg/day was selected
on the basis of the authors’ previous studies of ferutinin
effects on rat sexual behaviour (Zanoli et al., 2005;
Zavatti et al., 2006) as well as for preventing and
recovering osteoporosis (Palumbo et al., 2009; Cavani et
al., 2012). Estradiol benzoate (Estradiolo AMSA®,
Rome, Italy), used as a reference compound, was
dissolved in peanut oil and subcutaneously injected in a
volume of 0.3 mL per rat. The body weight of each
animal was recorded before ovariectomy and after 30
days of treatment. 
At the end of the treatment, all the rats were
sacrificed and soon after the uteri were removed, freed
from fat and weighed; mammary glands were also
collected. All samples were then fixed in sodium
phosphate (PBS) 4% buffered paraformaldehyde pH 7.4
solution, dehydrated in a graded series of ethanol and
embedded in paraffin. Cross sections (5 µm thick) were
cut and mounted on superfrost® plus slides (Menzel-
Glaser, Thermo scientific, Germany).
Morphology and morphometry
Morphological analyses were performed on uterus
and mammary gland sections stained with Gomori
trichrome and hematoxylin/eosin respectively, and
observed using a light microscope (Zeiss Axiophot -
Jena, West Germany) equipped with a camera (Nikon
DS-5Mc) connected to a computer. The image analysis
software used was NIS Elements AR, which enables
histomorphometric evaluation. The following parameters
were evaluated on three randomly selected sections of
the uterus/mammary gland for each animal: i) cross-
sectional areas of endometrium and myometrium; ii)
cross-sectional thickness of myometrium (cross-
sectional thickness of endometrium was not measured
due to its variable thickness in different zones of the
same section); iii) percentage of area of glandular
epithelium in relation to the total cross-sectional area of
endometrium; iiii) the percentage of area of glandular
epithelium in relation to the total cross-sectional area of
mammary gland. 
Immunohistochemistry (Ki-67)
For analysis of Ki-67 expression, the sections were
deparaffinized in three changes of xylene for 2 min each,
rehydrated and then subjected to heat-induced epitope
retrieval: they were immersed in a water bath of 10
mmol/L citrate buffer pH 6.0 for 30-40 min at 98° C and
then were cooled for 20 min. The sections were
subsequently exposed to 0.3% solution of hydrogen
peroxide for 5 min in order to deactivate endogenous
peroxidase activity. Sections were rinsed in tap water
and immunostaining was performed at room temperature
using a Benchmark XT automated immunostainer
(Ventana Medical Systems, Tucson, AZ). The slides
were incubated with 300 µL of primary monoclonal
mouse anti-human Ki-67 antigen clone MIB 1 (Dako
Italia Spa, Milan) diluted by 1:200 at approximately
37°C for 30 min with reagent diluent (Ventana Medical
Systems). After rinsing, the sections were incubated for
4 min with Avidin-Biotin blocking solution (Ventana
Medical Systems). 300 µL of the appropriate anti-mouse
biotinylated IgG-linking solution (Ventana Medical
Systems) was applied to each section for 4 min at room
temperature. Sections were again rinsed and allowed to
react with 300 µL of peroxidase-diaminobenzidine
(DAB Detection Kit) substrate solution (Ventana
Medical Systems) for 8 min, followed by counterstaining
with Hematoxylin for 1 min, then removed from the
autostainer, washed in warm water, dehydrated through
graded alcohols, cleared in xylene, and cover slipped.
Control reactions included: (1) sections incubated with
the omission of primary antibody and processed as
mentioned above, and (2) sections incubated with
normal mouse serum instead of the primary antibody and
processed as above.
Quantitative analysis was conducted by counting all
Ki-67-positive cells of uterus luminal/glandular and
breast glandular epithelia were counted on three
randomly selected Ki-67-processed sections for each
animal at x 40 magnification. The percentage of positive
cells both in epithelia of uterus and in terminal end buds
and alveoli of mammary gland was calculated in relation
to the total number of epithelial cells.
In situ end-labelling analysis (TUNEL - ApopTag®
Peroxidase Kits, Millipore)
Sections of uteri and mammary glands were
deparaffinated, rehydrated and then treated in a
humidified chamber with proteinase K (Boehringer,
Mannheim, Germany) at 20 µg ml-1 for 15 min at room
temperature, washed in bidistilled water, treated with 2%
H2O2 in methanol for 10 min at room temperature and
finally washed in bidistilled water. The slides were pre-
incubated with terminaldeoxynucleotidyl transferase
(TdT) buffer and 1 mM CoCl2 for 5 min at room
temperature and then incubated for 60 min in a
humidified chamber at 37°C with 50 µl TdT and
biotinylated deoxyuridine triphosphate (Bio dUTP)
(Boehringer) (TdT 0.3 U µl-1, Bio dUTP 8 µM in TdT
buffer and CoCl2 1 mM). The sections were then washed
four times in bidistilled apyrogen water (2 min each),
twice in phosphate-buffered saline (PBS) (5 min each),
in human serum albumin 2% (5 min) and in PBS (5
min), then covered with streptavidin-biotinylated
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peroxidise complex (Boehringer) diluted 1:100 in a
humidified chamber for 45 min at room temperature,
washed in PBS and stained with diaminobenzidine 50
mM (0.05%). The slides were finally washed in water
and counterstained with 0.5% methyl green for 10 min. 
Positive and negative controls were included in each
experiment. For the positive controls, sections were
treated with DNase I (1 µg ml-1) (Boehringer) in DNase
buffer for 10 min at room temperature before exposure
to biotinylated dUTP and TdT. For negative controls, the
sections were incubated without the TdT enzyme.
Quantitative analysis was conducted by counting all
TUNEL-positive cells of uterus luminal/glandular and
breast glandular epithelia on three randomly selected
TUNEL-sections for each animal at x40 magnification.
The percentage of immunostained cells in both
luminal/glandular epithelia of uterus and breast
glandular epithelia of terminal end buds and alveoli was
calculated in relation to the total number of epithelial
cells. 
Statistical analysis
One-way analysis of variance (ANOVA) with
Newman-Keuls test for post hoc comparisons was
performed using GraphPad Prism version 4.0 for
Windows (GraphPad Software, San Diego, California,
USA). Values of P<0.05 indicate significant differences
between the groups.
Results
The mean body weight values of all animal groups
recorded before ovariectomy (T0) and after 30 days of
treatment (T30) are shown in Figure 1A. No differences
in body weight were present at the beginning of the
experiment; after 30 days of treatment the body weight
of the EB-OVX and all F-OVX groups was significantly
lower compared to the C-OVX and SHAM groups.
Uterus
The uterine weights are shown in Figure 1B: the
mean values of SHAM, EB-OVX and all F-OVX groups
were significantly higher compared to the C-OVX
group; moreover, in all F-OVX animals the uterine
weight was always significantly lower compared to the
EB-OVX and SHAM groups.
Histological observations of uterine cross sections
are shown in Figure 2; it is possible to observe, at the
same enlargement, the atrophic aspect of the uterus in C-
OVX rats displaying a thin layer of endometrium and
myometrium compared to all other groups. Figure 3
shows the most representative features of the luminal
and glandular epithelia in the endometrium of all groups.
In SHAM rats the luminal and glandular epithelium is
mainly cylindrical monostratified. In C-OVX rats,
instead, the luminal epithelium is always cuboidal
monostratified, while the epithelial cells are higher in the
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Fig. 1. A. Mean body weights recorded before ovariectomy (T0) and
after 30 days of treatment (T30). B. Mean values of uterine weight.
Values are expressed as mean ± SEM. ***P<0.001 versus C-OVX;
#P<0.05, ##P<0.01, ###P<0.001 versus SHAM, +P<0.05, ++P<0.01
versus EB-OVX (ANOVA followed by Newman-Keuls test). SHAM
sham-operated controls receiving vehicle; C-OVX ovariectomized
controls receiving vehicle; EB-OVX ovariectomized treated with
estradiol benzoate; 0.5F-OVX, 1F-OVX, 2F-OVX ovariectomized
treated with ferutinin (0.5 mg/kg/day; 1 mg/kg/day; 2 mg/kg/day).
1031
Ferutinin effects on uterus and mammary gland in OVX rats
Fig. 2. Light microscopy, micrographs of Gomori trichrome-stained cross sections showing the uterine histology. SHAM sham-operated controls
receiving vehicle; C-OVX ovariectomized controls receiving vehicle; EB-OVX ovariectomized treated with estradiol benzoate; 0.5F-OVX, 1F-OVX, 2F-
OVX ovariectomized treated with ferutinin (0.5 mg/kg/day; 1 mg/kg/day; 2 mg/kg/day). x 25
Fig. 3. Light microscopy, micrographs of the endometrial luminal and glandular epithelia. SHAM sham-operated controls receiving vehicle; C-OVX
ovariectomized controls receiving vehicle; EB-OVX ovariectomized treated with estradiol benzoate; 0.5F-OVX,1F-OVX,2F-OVX ovariectomized treated
with ferutinin (0.5 mg/kg/day; 1 mg/kg/day; 2 mg/kg/day). Arrows indicate intracellular cysts in the luminal and glandular epithelia. x 200
glands, and the glandular lumen is small; moreover, the
endometrium shows high stromal cellularity. In EB-
OVX and in all F-OVX groups the luminal epithelium
cells were shaped differently: sometimes they showed a
cuboidal or cylindrical aspect with basally located
nuclei, in other cases they appeared pseudostratified.
The glandular epithelium was always cylindrical with a
high cytoplasm/nucleus ratio. In both epithelia,
intracellular cysts were present, indicative of cellular
degeneration. 
Morphometrical data are shown in Figures 4 and 5.
In C-OVX rats the endometrial area is significantly
lower compared to all other groups (Fig. 4A). All
animals treated with ferutinin show, compared to C-
OVX rats, an increase of the myometrial area (Fig. 4B)
and myometrial thickness (Fig. 4C), even if the values
are always lower than the EB-OVX and SHAM values;
sometimes these differences are statistically significant.
The percentages of glandular epithelium area in relation
to the cross-sectional area of endometrium are shown in
Figure 5: no statistical differences were observed among
all groups.
Histograms from immunohistochemistry data on
proliferation (revealed by Ki-67 reaction) in both
luminal and glandular epithelia are reported in Figure
6A,B: all F-OVX rats show a significant increase in
proliferation compared to all other groups; in particular,
the proliferation of the luminal epithelium in those rats
treated with the highest dose of ferutinin (2F-OVX) is
significantly lower then the other two F-OVX groups.
As regards cell apoptosis (revealed by TUNEL), the
percentage of positive cells in the luminal epithelium of
EB-OVX animals was the highest (Fig. 6C), while in
glandular epithelium only the 2F-OVX group exhibits
values significantly higher than all the other groups (Fig.
6D).
Mammary gland
Histological observations of mammary gland cross
sections are shown in Figures 7 and 8. In the SHAM
group, the parenchyma displays a normal aspect without
atypical features; it is possible to observe an abundant
stromal compartment rich in adipocytes. Secretory units
appear as clusters of tubules with a central lumen, lined
by cuboidal epithelial cells. In the C-OVX group the
stromal compartment is extremely abundant compared to
secretory units; all glandular epithelia were atrophic and
only a few secretory units were clearly detectable. In the
EB-OVX group, as well as in all F-OVX groups, the
glandular compartment is also abundant: the epithelium
is monostratified and the cell shape ranges from cuboidal
to columnar; sometimes intracellular cysts were present,
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Fig. 4. Mean values of endometrial (A), myometrial (B) areas and
myometrial thickness (C). Values are expressed as mean ± SEM.
**P<0.01, ***P<0.001 versus C-OVX; #P<0.05 versus SHAM; +P<0.05
versus EB-OVX (ANOVA followed by Newman-Keuls test). SHAM
sham-operated controls receiving vehicle; C-OVX ovariectomized
controls receiving vehicle; EB-OVX ovariectomized treated with estradiol
benzoate; 0.5F-OVX, 1F-OVX, 2F-OVX ovariectomized treated with
ferutinin (0.5 mg/kg/day; 1 mg/kg/day; 2 mg/kg/day).
Fig. 5. Mean values of the percentage of areas of glandular epithelium
in relation to the cross-sectional areas of endometrium. Values are
expressed as mean ± SEM (ANOVA followed by Newman-Keuls test).
SHAM sham-oper0ated controls receiving vehicle; C-OVX
ovariectomized controls receiving vehicle; EB-OVX ovariectomized
treated with estradiol benzoate; 0.5F-OVX, 1F-OVX, 2F-OVX
ovariectomized treated with ferutinin (0.5 mg/kg/day; 1 mg/kg/day; 2
mg/kg/day).
similar to those observed in the uterine epithelium of all
treated animals. 
Morphometrical evaluation of glandular epithelium
area in relation to the cross-sectional area of total gland
is reported as a percentage value in Figure 9A; in C-
OVX rats the value is significantly lower compared to
all other groups, as suggested by the morphological
observations (Fig. 7: C-OVX). 
Histograms from immunohistochemistry data on
proliferation of glandular epithelia of both terminal end
buds and alveoli are shown in Figure 9B: positivity of
Ki-67 immunostained nuclei was significantly higher in
mammary gland cells of EB-OVX animals compared to
0.5F-OVX, 1F-OVX and C-OVX rats. The percentage of
TUNEL positive cells counted in breast glandular
epithelia of both terminal end buds and alveoli is
reported in Figure 9C: the apoptotic index is
significantly higher for the 2F-OVX group relative to all
other groups, except the1F-OVX group. 
Discussion
The present study investigated the effects of one
month treatments with three different doses of ferutinin
on the uterus and mammary gland of OVX rats,
comparing the effects with those of estradiol benzoate
treatment. Attention was focused on cell proliferation
and apoptosis, since these cellular processes are strictly
correlated not only with physiological tissue turnover
but also the pathogenesis of cancer. The quantification of
these cellular processes is essential to evaluate the
therapeutic potential of the drugs (Tan et al., 2005). 
As regards body weight, the results confirm the
authors’ previously published data (Palumbo et al.,
2009), since in the OVX animals the treatment with
ferutinin (independently of the administered dose) and
estradiol benzoate counterbalances body weight increase
due to ovariectomy. 
As regards uterine weight, C-OVX rats show the
lowest values compared to all other groups, as expected
after ovariectomy, which implies uterine atrophy. This
atrophic condition in the C-OVX group involves a
significant reduction in both the endometrial and
myometrial areas. Despite this, the percentage value of
glandular area compared to the total endometrial area is
similar to all the other groups, the reduction of the
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Fig. 6. Mean values in endometrium of Ki-67-positive cell percentage in luminal (A) and glandular (B) epitelia and of TUNEL-positive cell percentage in
luminal (C) and glandular (D) epitelia. Values are expressed as mean ± SEM. ***P<0.001 versus C-OVX; #P<0.05, ###P<0.001 versus SHAM;
+++P<0.001 versus EB-OVX; °°°P<0.001 versus 0.5F-OVX; §§P<0.01, §§§P<0.001 versus 1F-OVX (ANOVA followed by Newman-Keuls test). SHAM
sham-operated controls receiving vehicle; C-OVX ovariectomized controls receiving vehicle; EB-OVX ovariectomized treated with estradiol benzoate;
0.5F-OVX, 1F-OVX, 2F-OVX ovariectomized treated with ferutinin (0.5 mg/kg/day; 1 mg/kg/day; 2 mg/kg/day).
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Fig. 7. Light microscopy, micrographs of hematoxylin/eosin-stained cross sections showing the mammary gland histology. SHAM sham-operated
controls receiving vehicle; C-OVX ovariectomized controls receiving vehicle; EB-OVX ovariectomized treated with estradiol benzoate; 0.5F-OVX, 1F-
OVX, 2F-OVX ovariectomized treated with ferutinin (0.5 mg/kg/day; 1 mg/kg/day; 2 mg/kg/day). x 50
Fig. 8. Light microscopy, micrographs of hematoxylin/eosin-stained cross sections showing the histology of mammary gland alveoli. SHAM sham-
operated controls receiving vehicle; C-OVX ovariectomized controls receiving vehicle; EB-OVX ovariectomized treated with estradiol benzoate; 0.5F-
OVX, 1F-OVX, 2F-OVX ovariectomized treated with ferutinin (0.5 mg/kg/day; 1 mg/kg/day; 2 mg/kg/day). x 400
glandular component probably being proportional to the
decrease of the total endometrium. The lower uterine
weight recorded in all F-OVX rats compared to EB-
OVX rats might be ascribed to the reduction of the
myometrium due, in turn, to ferutinin treatment. 
When discussing the uterine morphological and
immunohistochemical data, it is important to remember
that rats have an average estrus cycle of 4-5 days divided
into four phases (proestrus, estrus, metestrus and
diestrus), characterized by morphological changes
particularly affecting uterine endometrium (Westwood,
2008), even if the criteria to define the end of one phase
and the beginning of the next are not exactly clear. In the
first phase, proestrus, the epithelial cells of the
endometrium are cuboidal or columnar and mitoses are
present; in the estrus phase there is degeneration of the
columnar epithelial cells in parallel with loss of their
mitotic activity; in the metestrus phase the epithelium is
similar to the estrus phase, but with an increase in
mitotic activity; in the final phase, diestrum, the lumen is
lined by columnar epithelial cells, mitoses are rare and
degenerative cells are only occasionally present.
On the basis of the above considerations, our
morphological data suggest that SHAM animals are
likely in the diestrus phase; in fact, with few cellular
mitoses and scanty apoptosis occur, as confirmed by the
immunohistochemical data (Fig. 6). In EB-OVX
animals, whose administration of estradiol benzoate is
supposed to mime the physiological hormonal cycle, the
histological features seem to resemble the estrus phase
in which only few mitoses are present; this might
explain the low proliferation rate recorded in EB-OVX
animals. All animals treated daily with ferutinin show
histological features similar to those of the metestrus
phase, with degeneration of luminal and glandular
epithelial cells, as shown by the abundant intraepithelial
cysts. Treatment with increasing doses of ferutinin
determines on one hand a decrease in cell proliferation
(Ki-67), and on the other hand an increase in the
apoptotic index (TUNEL) of the luminal epithelium and,
to a greater extent, of the glandular uterine epithelium,
which represents the most frequent site of carcinoma
onset. In particular, a 2 mg/kg/day dose of ferutinin
would seem to offer a better protective action against
uterine carcinoma compared to lower doses, since in 0.5
and 1F-OVX rats the high proliferation is not
counterbalanced by high apoptosis. In this context, it is
interesting to deduce that the ratio between the
percentage of proliferating cells and the percentage of
apoptotic cells is higher in the glandular epithelia of EB-
OVX rats compared to 2F-OVX rats (Fig. 6B versus
6D).
As far as the mammary gland is concerned, it
represents a complex organ in which the glandular tissue
is widely dispersed in fat tissue, thus making
morphological analysis extremely difficult (Masso-
Welch et al., 2000; Hilakivi-Clarke and Assis, 2006).
Both morphological and morphometrical results show
that estradiol benzoate, as well as ferutinin, exert a
trophic effect on mammary gland epithelial tissue with
respect to C-OVX animals. Regarding cell proliferation,
treatment with estradiol benzoate determines a
significant increase in glandular cell proliferation
compared to ferutinin in lower doses. Despite the
absence of significant differences in glandular
proliferation between EB-OVX and 2F-OVX animals,
the amount of glandular cell apoptosis in 2F-OVX rats is
the highest value recorded among all groups, with
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Fig. 9. Mean values of (A) the percentage of areas of glandular
epithelium in relation to the cross-sectional areas of total glands, (B) Ki-
67-positive cell percentage in breast glandular epithelia of terminal end
buds and alveoli and (C) TUNEL-positive cell percentage in breast
glandular epithelia of terminal end buds and alveoli. Values are
expressed as mean ± SEM, *P<0.05, **P<0.01, ***P<0.001 versus C-
OVX; #P<0.05 versus SHAM; +P<0.05, ++P<0.01 versus EB-OVX;
°P<0.05 versus 0.5F-OVX (ANOVA followed by Newman-Keuls test).
SHAM sham-operated controls receiving vehicle; C-OVX
ovariectomized controls receiving vehicle; EB-OVX ovariectomized
treated with estradiol benzoate; 0.5F-OVX, 1F-OVX, 2F-OVX
ovariectomized treated with ferutinin (0.5 mg/kg/day; 1 mg/kg/day; 2
mg/kg/day).
statistical significance. These last results suggest that
ferutinin at the dose of 2 mg/Kg/day might offer a
protective action against breast cancer compared to both
ferutinin in lower doses and estradiol benzoate.
In conclusion, the present data suggest that the
effects of ferutinin are dose dependent, and that a 2
mg/kg/day dose might provide a better protective action
against the onset of both breast and uterine carcinoma
compared to lower doses of ferutinin or estradiol
benzoate, increasing cellular apoptosis in glandular
epithelia. These results bring new insights into the
actions of ferutinin, agreeing with the data recently
published by the authors on bone tissue (Cavani et al.,
2012), demonstrating that a 2 mg/kg/day dose exerts a
greater osteoprotective effect in OVX rats compared to
estrogens and lower ferutinin doses, particularly in
skeletal regions with higher metabolic activity,
presumably by inhibiting osteoclast activity rather than
increasing bone deposition.
On the basis of these observations, the authors
underline the importance of further research into diets
implemented with ferutinin, in order to better evaluate
the possibility of employing this phytoestrogen as a
“safe” good alternative drug to the use of estrogens in
HRT in menopause.
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